Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AN2728 · 1 trial · 1 indication
12-lead ECG, clinical laboratory tests, urinalysis, spontaneous/elicited adverse event (AE) reporting, local site reactions, physical exam and vital signs (blood pressure, heart rate).
| Arm | Type | Description |
|---|---|---|
| Cohort 1: AN2728 Ointment | ACTIVE_COMPARATOR | - |
| Cohort 1: AN2728 Vehicle | PLACEBO_COMPARATOR | - |
| Cohort 3: AN2728 Ointment | ACTIVE_COMPARATOR | - |
| Cohort 3: AN2728 Vehicle | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| AN2728 Ointment | DRUG | 5mg/cm2, BID |
| AN2728 Vehicle | DRUG | 5mg/cm2 BID |
Inclusion Criteria: * White males, 18 - 55 years (inclusive) of age at the time of randomization. * Body weight between 60-90 kg (Body Mass Index \[BMI\] between 19 and 30 kg/m2 \[inclusive\]). * Willing and able to comply with study instructions and commit to all follow-up visits. * Have adequate ...
AN2728 is an investigational small molecule being developed for dermatology conditions, specifically plaque-type psoriasis and atopic dermatitis. Clinical trials have evaluated it as a topical ointment for mild-to-moderate atopic dermatitis in adults and adolescents, and for plaque-type psoriasis. It is not FDA approved and remains in clinical development.
AN2728 is being developed by Pfizer, Inc., which trades under the ticker symbol PFE. The company has sponsored clinical trials of the drug across multiple countries, including the United States and Australia.
AN2728 is in Phase 1 and Phase 2 clinical development. Completed trials include Phase 1 safety studies and Phase 2 efficacy studies for atopic dermatitis and plaque-type psoriasis. The drug is investigational and has not received FDA approval.
AN2728 has been studied in several completed trials, including NCT01258088 for plaque-type psoriasis, NCT01301508 for atopic dermatitis, NCT01602341 for adolescents with atopic dermatitis, and NCT01652885 for safety and pharmacokinetics in adolescents. All six trials are completed with no active trials ongoing.
AN2728 is not the same as AN2898, but they have been studied together. A Phase 2 trial, NCT01301508, evaluated the efficacy and safety of both AN2898 and AN2728 topical ointments for treating mild-to-moderate atopic dermatitis.